74048-23-0

Upstream product

• 74048-21-8 1-nitro-1,2-diphenyl-1-pentene-3-one 
• 37928-17-9 5-methyl-3,4-diphenyl isoxazole 
• 74-88-4 methyl iodide 
• 91711-66-9 (E)-1,2-diphenylpent-1-en-3-one 
• 181696-73-1 3,4-diphenyl-4-hydrido-5-hydroxy-5-methylisoxazole 

Relevant academic research and scientific papers

Functionalized diarylisoxazoles inhibitors of ciclooxygenase

The present invention refers to isoxazole derivatives, in particular diarylisoxazole derivatives inhibitors of cyclooxygenase (COX), in particular cyclooxygenase-1 (COX-1), to their pharmaceutical compositions, the process for their preparation and their use for the chemoprevention and treatment of inflammatory syndromes and in the prevention and treatment of carcinomas, in particular intestinal, ovarian and cutaneous carcinomas, in the treatment of pain syndromes, in particular after surgery, and in the cardiovascular field as antithrombotics/vasoprotectives/cardioprotectives.

ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS

The present invention refers to isoxazole derivatives, in particular 3,4-diaryl isoxazole derivatives, to their pharmaceutical compositions, the process for preparing them and their use as inhibitors of cycloosygenase, in particular of cycloosygenase 1 and 2 (COX-1) (COX-2). The present invention also refers to a process for determining the potential toxicity of compounds that inhibit cycloosygenase (COX), in particular cycloosygenase-2 (COX-2) isoform, and to the use of compounds that inhibit cycloosygenase (COX), in particular cycloosygenase-2 (COX-2) and their pharmaceutical compositions, in subjects for whom the potential cardiovascular toxicity of said compounds is reduced.

Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: Reversal cyclooxygenase-2 selectivity by sulfonamide group removal

3,4-Diarylisoxazole analogues of valdecoxib [4-(5-methyl-3-phenylisoxazol- 4-yl)-benzensulfonamide], a selective cyclooxygenase-2 (COX-2) inhibitor, were synthesized by 1,3-dipolar cycloaddition of arylnitrile oxides to the enolate ion of phenylacetone regioselectively prepared in situ with lithium diisopropylamide at 0 °C. The corresponding 3-aryl-5-methyl-4-phenyl- isoxazoles were easily generated by a dehydration/aromatization reaction under basic conditions of 3-aryl-5-hydroxy-5-methyl-4-phenyl-2-isoxazolines and further transformed into their benzenesulfonamide derivatives. The biochemical COX-1/COX-2 selectivity was evaluated in vitro by using the human whole blood assays of COX isozyme activity. Three compounds not bearing the sulfonamide group present in valdecoxib were selective COX-1 inhibitors.